AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02612246
Drug: GLPG1972 single ascending doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral solution
Trial: NCT02612246
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral solution, matching placebo
Trial: NCT02612246
Drug: Placebo multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses, daily for 14 days, oral solution
Trial: NCT02141321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00624845
Drug: OMS103HP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum 6 bags of OMS103HP irrigation solution
Trial: NCT00624845
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 6 bags of vehicle irrigation solution
Trial: NCT00828282
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
Trial: NCT01710033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tables twice daily (BID) for 28 days
Trial: NCT01710033
Drug: CP-690,550 5 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 5 mg BID for 28 days
Trial: NCT01710033
Drug: CP-690,550 15 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 15 mg BID for 28 days
Trial: NCT01710033
Drug: CP-690,550 30 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 30 mg BID for 28 days
Trial: NCT04171687
Drug: RAPA113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAPA113 tablet
Trial: NCT05795907
Drug: SAR443820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule / Oral
Trial: NCT05795907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Capsule / Oral
Trial: NCT01282073
Drug: Mycophenolate mofetil, low dose steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 \~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks
Trial: NCT00671307
Drug: rhu-pGelsolin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
Trial: NCT02491879
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5% Ketoprofen gel with a 2 g local use
Trial: NCT02004626
Drug: Kollagenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records.
Trial: NCT01425814
Drug: LAS100977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder inhalation,Once daily, single dose
Trial: NCT01425814
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder inhalation (capsule),single dose
Trial: NCT01425814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
Trial: NCT03461718
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard sedation regimen
Trial: NCT00002529
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
Trial: NCT00002529
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
Trial: NCT00671307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control given as IV infusion over 1 hour
Trial: NCT04276207
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by CSII
Trial: NCT01697111
Drug: EE20/DRSP(BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
Trial: NCT01697111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively
Trial: NCT04943237
Drug: Anti-TNF agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group of patients using anti-TNF for the last 5 years.
Trial: NCT04943237
Drug: Conventional therapy users for the last 5 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
Trial: NCT01263119
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18-mg LY2216684 oral dose
Trial: NCT03101800
Drug: Azathioprine and Allopurinol
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
Trial: NCT03101800
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard weight based azathioprine dosage
Trial: NCT02138825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
Trial: NCT02415556
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin 40 IU daily over 24 weeks
Trial: NCT02415556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sterile saline 40 IU daily over 24 weeks
Trial: NCT01752049
Drug: placebo saline drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
Trial: NCT01195974
Drug: GSK2248761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
Trial: NCT01020357
Drug: Caffeine citrate injection
RxNorm normalized name: Caffeine Citrate Injection
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
Trial: NCT01020357
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT02429817
Drug: Technetium-99m - Diethylenetriaminepentaacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-DTPA solution placed on the nebulizer reservoir
Trial: NCT00998257
Drug: EE20/DRSP (YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients under daily life treatment with YAZ according to local drug information.
Trial: NCT02900430
Drug: Patients with antifungal prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
Trial: NCT01475721
Drug: ADVAIR 100/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
Trial: NCT01475721
Drug: ADVAIR 250/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Trial: NCT01475721
Drug: ADVAIR 500/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
Trial: NCT05499026
Drug: Chenodeoxycholic Acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bile acid
Trial: NCT01198587
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid.
Trial: NCT01198587
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
Trial: NCT00986882
Drug: SAF312A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00986882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00986882
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04167943
Drug: Dual cured resin modified tricalcium silicate cement
RxNorm normalized name: dicalcium silicate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A resin based, dual cured tricalcium silicate based cement
Trial: NCT00000395
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002766
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002766
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002766
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002766
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00402987
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
Trial: NCT00402987
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
Trial: NCT00402987
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
Trial: NCT00402987
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1 placebo followed 6-12 hours later by dose 2 placebo
Trial: NCT00003816
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02133573
Drug: Vaginal lubricant
RxNorm normalized name: Film, Multi Ingredient Vaginal Film [VCF VAGINAL LUBRICANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
Trial: NCT02526914
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
Trial: NCT00738296
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
Trial: NCT00738296
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
Trial: NCT00738296
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
Trial: NCT02431325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01917318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During 8 weeks subjects will receive oral placebo
Trial: NCT03218917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once per day for 24 weeks
Trial: NCT01472250
Drug: Clinical chemo-drugs
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel
Trial: NCT02489344
Drug: GZ/SAR402671
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT02786407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In these studies,patients received placebo administered to 20 injection sites
Trial: NCT03195569
Drug: QL1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
Trial: NCT03195569
Drug: Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
Trial: NCT02065219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
Trial: NCT00740181
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03464266
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
Trial: NCT01908010
Drug: ABT-354
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-354 Low Dose
Trial: NCT01908010
Drug: ABT-354
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-354 High Dose
Trial: NCT01908010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01940419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml sodium chloride iv administered over 10 minutes just before surgery
Trial: NCT00572819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
Trial: NCT01955161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, matching placebo capsules, orally
Trial: NCT03229668
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule administered 1 hour prior to the surgical operation
Trial: NCT02874092
Drug: MTX therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01677988
Drug: Neo-adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~2. Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~   1. Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~  2. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation.
Trial: NCT01974284
Drug: percutaneous ethanol ablation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
Trial: NCT01332656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Trial: NCT02594839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of 400 mL saline
Trial: NCT00484263
Drug: Hypertonic saline 6% -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
Trial: NCT02665260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical liquid
Trial: NCT00267930
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01442987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, P.O. 8week
Trial: NCT00267176
Drug: lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00545779
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg orally once monthly for 6 months
Trial: NCT01005290
Drug: Combination pill
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
Trial: NCT03720470
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~1. In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~2. In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16.
Trial: NCT03720470
Drug: Injectable Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
Trial: NCT00916448
Drug: E. coli endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
Trial: NCT02959047
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ every 2 weeks
Trial: NCT03388619
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
Trial: NCT02408939
Drug: Stress-dose hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
Trial: NCT01237873
Drug: Ali/Amlo 150/2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg